| Date | Title | | | 02/23/10 | Cephalon Exercises its Option to Acquire Ception Therapeutics| Ception Delivers Positive Results from a Phase II Study of CINQUIL in Adult Eosinophilic Asthma
FRAZER, Pa. and MALVERN, Pa., Feb 23, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma. A Phase II clinical trial of Ception's lead compound, CINQUIL(TM) (reslizumab), in 106 patients demonstrated improved asth... |
|  | | 02/11/10 | Cephalon Reports Record Sales and Adjusted Net Income for 2009| --Sales Exceed $2 Billion, Increasing for Tenth Year in a Row --2010 Guidance Increased --Cash From Operations Totals $681 MillionFRAZER, Pa., Feb 11, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2009 net sales of $2.152 billion, an 11 percent increase compared to net sales of $1.943 billion for 2008. Basic income per common share for the year was $4.74. Excluding amortization expense and certain other items, adjusted net income for full year 2009 was $469 mill... |
| | | 02/01/10 | Cephalon, Inc. Announces Agreement to Acquire Mepha AG| Expands Range of Products and Reach in Europe, Africa, and the Middle East
Transaction Expected to be Immediately Accretive to Adjusted Earnings Per Share
FRAZER, Pa., AESCH, Switzerland, and MAISONS-ALFORT, France, Feb 01, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company. Mepha has specific expertise in innovative dosage formul... |
| | | 01/28/10 | Cephalon Announces Executive Leadership Changes| FRAZER, Pa., Jan 28, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced the promotion of three executives, Kevin Buchi, Wilco Groenhuysen and Alain Aragues.
Kevin Buchi is promoted to a new position as Chief Operating Officer with responsibility for Worldwide Pharmaceutical Operations, Worldwide Technical Operations, Investor Relations and Business Development. Mr. Buchi joined Cephalon in 1991 and became Chief Financial Officer (CFO) in 1996.
"During his 18 years... |
| |
|
Print Page | 
Email Page | 
RSS Feeds | 
Financial Tear Sheet